Browse by Poster Presenter

Type here to filter the list

C
Cagney, Gerard

University College Dublin
(P 235) ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Gerard Cagney
Favorite
Cain, Julie

Beatson West of Scotland Cancer Centre
(P 073) EVALUATING DISTRESS AND THE PATIENT EXPERIENCE OF SARCOMA PATIENTS IN THE WEST OF SCOTLAND
Julie Cain
Favorite
Cai, Shirong

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080
(P 101) CYTOREDUCTIVE SURGERY FOR METASTATIC GASTROINTESTINAL STROMAL TUMORS TREATED WITH RIPRETINIB: A SINGLE-CENTER ANALYSIS.
Shirong Cai
Favorite
Cai, Zhenyu

Peking University People.s Hospital
(P 021) DISTINCT GENOMIC FEATURES BETWEEN OSTEOSARCOMAS FIRSTLY METASTASING TO BONE AND TO LUNG
Zhenyu Cai
Favorite
Calabrò, Luana

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Luana Calabrò
Favorite
Calabrese, Chiara

Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Chiara Calabrese
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Chiara Calabrese
Favorite
Callan, Alexandra

UT Southwestern
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Alexandra Callan
Favorite
(P 035) RISK FACTORS FOR BONY METASTASES IN PEDIATRIC OSTEOSARCOMA PATIENTS
Alexandra Callan
Favorite
Callegaro, Dario

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Dario Callegaro
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Dario Callegaro
Favorite
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Dario Callegaro
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Dario Callegaro
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Dario Callegaro
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Dario Callegaro
Favorite
Calpona, Sebastino

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Sebastino Calpona
Favorite
Calvert, George

Norton Cancer Institute
(P 071) DEVELOPMENT OF A COLLABORATIVE SARCOMA REGISTRY: STRATEGIES TO DECREASE PROVIDER BURDEN AND INCREASE ENGAGEMENT
George Calvert
Favorite
Calvo-Pérez, Juan Carlos

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Juan Carlos Calvo-Pérez
Favorite
Camano, Melisa

Unidad de Patología Oncológica Musculo Esquelética, Instituto Nacional de Ortopedia y Traumatología
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Melisa Camano
Favorite
Cam, Maren

Center for Childhood Cancer, Nationwide Children's Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Maren Cam
Favorite
Cammelli, Manuela

Humanitas University
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Manuela Cammelli
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Manuela Cammelli
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Manuela Cammelli
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Manuela Cammelli
Favorite
Campanacci, Domenico Andrea

Department of Orthopaedic Oncology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Domenico Andrea Campanacci
Favorite
Campbell-Hewson, Quentin

The Great North Children's Hospital, Royal Victoria Infirmary
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Quentin Campbell-Hewson
Favorite
Campbell, Matthew

UT Southwestern Medical Center
(P 035) RISK FACTORS FOR BONY METASTASES IN PEDIATRIC OSTEOSARCOMA PATIENTS
Matthew Campbell
Favorite
Campoverde, Leticia

University of Miami/Sylvester Comprehensive Cancer Center
(P 07) HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Leticia Campoverde
Favorite
Campoverde, Leticia

University of Miami
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Leticia Campoverde
Favorite
Cananzi, Ferdinando

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy. Sarcoma, Melanoma and Rare Tumors Surgery Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Ferdinando Cananzi
Favorite
Cananzi, Ferdinando Carlo Maria

Sarcoma Surgery Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Ferdinando Carlo Maria Cananzi
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Ferdinando Carlo Maria Cananzi
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Ferdinando Carlo Maria Cananzi
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Ferdinando Carlo Maria Cananzi
Favorite
(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Ferdinando Carlo Maria Cananzi
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Ferdinando Carlo Maria Cananzi
Favorite
Cannon, Matthew

Center for Childhood Cancer, Nationwide Children's Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Matthew Cannon
Favorite
Cantor, Emma

Children's Hospital Los Angeles
(P 151) CLINICAL PRESENTATION OF OSTEOSARCOMA PATIENTS WITH ACUTE METHOTREXATE TOXICITY TREATED WITH GLUCARPIDASE
Emma Cantor
Favorite
Cantor, Nicole

Campbell University School of Osteopathic Medicine
(P 288) LOCKING PLATE AUGMENTATION OF POLYMETHYLMETHACRYLATE-FILLED DISTAL FEMUR DEFECTS
Nicole Cantor
Favorite
Caragea, Mara

University of Calgary
(P 205) PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Mara Caragea
Favorite
Cardenas, Enrique

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Enrique Cardenas
Favorite
Cardona, Kenneth

Winship Cancer Institute, Emory University
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Kenneth Cardona
Favorite
Cariboni, Umberto

Division of Thoracic Surgery, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Umberto Cariboni
Favorite
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Umberto Cariboni
Favorite
Carnero, Amancio

Instituto de Biomedicina de Sevilla (IBiS)
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Amancio Carnero
Favorite
Carrère, Sébastien

Surgical Oncology, Institut régional du Cancer Montpellier
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Sébastien Carrère
Favorite
Carr-Ascher, Janai

University of California, Davis
(P 251) TARGETING SOFT TISSUE SARCOMA CANCER STEM CELLS IMPROVES DOXORUBICIN SENSITIVITY IN VITRO
Janai Carr-Ascher
Favorite
Carrasco, Irene

Hospital Virgen del Rocio
(P 113) PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
Irene Carrasco
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Irene Carrasco
Favorite
(P 267) EFFICACY OF SORAFENIB IN PRETREATED DESMOID TUMORS. EXPERIENCE OF A HIGH-VOLUME CENTER.
Irene Carrasco
Favorite
Carroll, Mark

Adaptimmune
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Mark Carroll
Favorite
Casadei, Roberto

Orthopedic Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Roberto Casadei
Favorite
Casado Herraez, Antonio

Hospital Universitario San Carlos
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Antonio Casado Herraez
Favorite
Casado, Antonio

HU Clinico San Carlos
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Antonio Casado
Favorite
Casales, Nicolas

Unidad de Patología Oncológica Musculo Esquelética, Instituto Nacional de Ortopedia y Traumatología
(P 077) FREEZING IN FLORIDA: ARE WE READY FOR DIVERSITY?
Nicolas Casales
Favorite
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Nicolas Casales
Favorite
Casali, Paolo

University of Milan
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Paolo Casali
Favorite
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Paolo Casali
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Paolo Casali
Favorite
(P 162) PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Paolo Casali
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Paolo Casali
Favorite
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Paolo Casali
Favorite
Casanova, Michela

Paediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Michela Casanova
Favorite
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Michela Casanova
Favorite
Cascales, Pedro

Hospital clínico universitario virgen de la Arrixaca
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Pedro Cascales
Favorite
Casey, Dana

UNC at Chapel Hill
(P 155) LATE EVENTS OCCURRING AFTER 5 YEARS IN PEDIATRIC RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Dana Casey
Favorite
Cassier, Philippe

CENTRE LEON BERARD
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Philippe Cassier
Favorite
Cassou-Mounat, Thibaut

IUCT Oncopole
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Thibaut Cassou-Mounat
Favorite
Castelli, Chiara

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Chiara Castelli
Favorite
Castex, Marie-Pierre

CHU Toulouse
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Marie-Pierre Castex
Favorite
Castillo Orozco, Ana

Department of Human Genetics, McGill University
(P 030) OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Ana Castillo Orozco
Favorite
(P 232) DECIPHERING METASTASIS MAINTENANCE AND CHEMO RESISTANCE EVENTS IN CIC-DUX4 SARCOMA
Ana Castillo Orozco
Favorite
Catton, Charles

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Charles Catton
Favorite
Cavaliere, Silvia

Campus Bio-Medico University of Rome
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Silvia Cavaliere
Favorite
Cayuela Fuentes, Valentín

Hospital Universitario Virgen de la Arrixaca
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Valentín Cayuela Fuentes
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Valentín Cayuela Fuentes
Favorite
Celant, Simone

Italian Medicines Agency, Rome, Italy
(P 162) PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Simone Celant
Favorite
Cereda, Matteo

Department of Biosciences, University of Milan and Italian Institute for Genomic Medicine (Candiolo, Turin))
(P 029) MOLECULAR CHARACTERIZATION OF OSTEOSARCOMA AND EWING SARCOMA IN PEDIATRIC PATIENTS REVEALS NOVEL RNA-BASED INTERVENTION POINTS.
Matteo Cereda
Favorite
Cerezuela Fernández de Palencia, Álvaro

Hospital Universitario Virgen de la Arrixaca
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Álvaro Cerezuela Fernández de Palencia
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Álvaro Cerezuela Fernández de Palencia
Favorite
Cesari, Marilena

Chemotherapy Unit, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Marilena Cesari
Favorite
(P 031) PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE
Marilena Cesari
Favorite
Cesaro, Edoardo

Department of Precision Medicine, Università degli Studi della Campania “L. Vanvitelli”
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Edoardo Cesaro
Favorite
Chabaud, Sylvie
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Sylvie Chabaud
Favorite
Chakka, Anish

University of Pittsburgh Cancer Bioinformatics Services
(P 244) MUTATIONAL BURDEN OF COPY NUMBER VARIANTS VS STRUCTURAL VARIANTS IN EXTRASKELETAL MYXOID CHONDROSARCOMA: A CASE STUDY
Anish Chakka
Favorite
Chakrabarty, Nivedita

Tata Memorial Centre, Mumbai
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Nivedita Chakrabarty
Favorite
Chami, Rose

Hospital for Sick Children and University of Toronto
(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Rose Chami
Favorite
Chamorro-Pérez, Jesús

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Jesús Chamorro-Pérez
Favorite
Chamoun, Roukoz

The University of Kansas Health System
(P 028) LONG TERM SURVIVAL OF AN ANTERIOR SKULL BASE OSTEOSARCOMA ARISING FROM FIBROUS DYSPLASIA TREATED WITH TRIMODALITY THERAPY
Roukoz Chamoun
Favorite
Chan, Angela Zaneta

Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong
(P 210) A LONGITUDINAL ANALYSIS OF PROGNOSTIC FACTORS IN CHINESE PATIENTS WITH RETROPERITONEAL LIPOSARCOMA
Angela Zaneta Chan
Favorite
Chan, Carlos

Univeristy of Iowa Hospitals & Clinics
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Carlos Chan
Favorite
Chan, Corey

Translational and Clinical Research Institute, Newcastle University, UK
(P 172) DEVELOPMENT OF A TARGETED DUAL-MODALITY RADIOIMMUNOCONJUGATE FOR IMAGE GUIDED SARCOMA SURGERY
Corey Chan
Favorite
Chang, Shantel

Gold Coast University Hospital
(P 299) PULMONARY METASTASECTOMY OF OSTEOSARCOMA VIA PNEUMONECTOMY AND MEDIAN STERNOTOMY WITH COMPLETE INTRATHORACIC LIVER MIGRATION: A CASE REPORT
Shantel Chang
Favorite
Chang, Vivian

UCLA
(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Vivian Chang
Favorite
Chan, Jason

National Cancer Centre Singapore
(P 174) ESTABLISHMENT AND CHARACTERIZATION OF A PATIENT-DERIVED SOLITARY FIBROUS TUMOR/HEMANGIOPERICYTOMA CELL LINE MODEL
Jason Chan
Favorite
Chan, Jason

MSKCC
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Jason Chan
Favorite
Chan, Sharon

Cancer Science Institute of Singapore
(P 196) THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Sharon Chan
Favorite
Chantharasamee, Jomjit

Siriraj Hospital, Mahidol University, Bangkok, Thailand
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Jomjit Chantharasamee
Favorite
Chan, Timothy

Cleveland Clinic
(P 249) SARCOMA GENE FUSION BREAKPOINTS: NON-RANDOM EVENT PATTERNS IN SARCOMAS WITH GENE FUSIONS INCLUDING EWING SARCOMA, DSRCT, RHABDOMYOSARCOMA, SYNOVIAL SARCOMA, CCNB3-BCOR, AND CIC-DUX
Timothy Chan
Favorite
Chan, Wei Yen

Chris O'Brien Lifehouse
(P 149) CHARACTERISTICS OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS REFERRED TO A DEDICATED EARLY PHASE CLINICAL TRIAL CLINIC
Wei Yen Chan
Favorite
Chao, Joseph

City of Hope
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Joseph Chao
Favorite
Charisi, Maria

Monopar Therapeutics Inc.
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Maria Charisi
Favorite
Chau, Bonny

University of Washington
(P 063) A RETROSPECTIVE COHORT ANALYSIS EVALUATING THE NATURAL HISTORY AND CHARACTERISTICS OF ANGIOSARCOMAS OF THE BREAST
Bonny Chau
Favorite
Chauffert, Bruno

CH SAINT QUENTIN
(P 080) INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Bruno Chauffert
Favorite
Chawla, Sant

Sarcoma Oncology Research Center
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Sant Chawla
Favorite
(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Sant Chawla
Favorite
(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Sant Chawla
Favorite
(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Sant Chawla
Favorite
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Sant Chawla
Favorite
(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Sant Chawla
Favorite
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Sant Chawla
Favorite
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Sant Chawla
Favorite
(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Sant Chawla
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Sant Chawla
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Sant Chawla
Favorite
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Sant Chawla
Favorite
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Sant Chawla
Favorite
Chen, Benjamin

Institute of Molecular and Cell Biology, A*STAR, Singapore
(P 196) THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Benjamin Chen
Favorite
Chen, Chun-Yu

Center for Childhood Cancer, Nationwide Children's Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Chun-Yu Chen
Favorite
Cheng, Sylvia

B.C. Children’s Hospital
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Sylvia Cheng
Favorite
Chen, Huawei (Ray)

Zentaur Therapeutics
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Huawei (Ray) Chen
Favorite
Chen, James

Ohio State University
(P 177) GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
James Chen
Favorite
(P 256) TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA
James Chen
Favorite
Chen, Jun

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(P 211) ANESTHESIA MANAGEMENTS AND POSTOPERATIVE MORTALITIES IN RETROPERITONEAL SARCOMA PATIENTS EXPERIENCING MASSIVE BLOOD TRANSFUSION DURING SURGERIES
Jun Chen
Favorite
(P 216) LONG TERM SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH PRIMARY RETROPERITONEAL LEIOMYOSARCOMA UNDERGOING SURGERIES: REAL WORLD DATA FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Jun Chen
Favorite
(P 222) SURGICAL RESECTION OF ABDOMINOPELVIC AGGRESSIVE ANGIOMYXOMA: A RETROSPECTIVE REVIEW OF 12 CONSECUTIVE CASES
Jun Chen
Favorite
(P 223) SURGICAL RESECTION OF RETROPERITONEAL LEIOMYOSARCOMA IN 97 CONSECUTIVE PATIENTS - EXPERIENCES FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Jun Chen
Favorite
Chen, Mu-Kai

Department of Dermatology, First Affiliated Hospital of Sun Yat-Sen University
(P 111) PLASMA CONCENTRATION MONITORING AND PERSONALIZED DESENSITIZATION THERAPY IN PATIENTS OF GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB-ASSOCIATED SKIN RASH
Mu-Kai Chen
Favorite
Chen, Sile

Gastrointestinal Surgery Center, The First Affiliated Hospital of Sun Yat-sen University
(P 111) PLASMA CONCENTRATION MONITORING AND PERSONALIZED DESENSITIZATION THERAPY IN PATIENTS OF GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB-ASSOCIATED SKIN RASH
Sile Chen
Favorite
Chen, Victoria

Boehringer Ingelheim Pharmaceuticals Inc
(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Victoria Chen
Favorite
Chen, Weida

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(P 216) LONG TERM SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH PRIMARY RETROPERITONEAL LEIOMYOSARCOMA UNDERGOING SURGERIES: REAL WORLD DATA FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Weida Chen
Favorite
(P 222) SURGICAL RESECTION OF ABDOMINOPELVIC AGGRESSIVE ANGIOMYXOMA: A RETROSPECTIVE REVIEW OF 12 CONSECUTIVE CASES
Weida Chen
Favorite
(P 223) SURGICAL RESECTION OF RETROPERITONEAL LEIOMYOSARCOMA IN 97 CONSECUTIVE PATIENTS - EXPERIENCES FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Weida Chen
Favorite
Chen, Xiao

Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University
(P 111) PLASMA CONCENTRATION MONITORING AND PERSONALIZED DESENSITIZATION THERAPY IN PATIENTS OF GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB-ASSOCIATED SKIN RASH
Xiao Chen
Favorite
Chen, Xiao

Mayo Clinic (Rochester)
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Xiao Chen
Favorite
(P 291) OUTCOME OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE UPPER EXTREMITY
Xiao Chen
Favorite
(P 293) OUTCOMES OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE LOWER EXTREMITY
Xiao Chen
Favorite
(P 296) PET IMAGING VERSUS CLINICAL EXAMINATION IN DETERMINING LYMPH NODE INVOLVEMENT IN MERKEL CELL CARCINOMA OF THE EXTREMITY
Xiao Chen
Favorite
Chen, Xiaobing

Department of Retroperitoneal Tumor Surgery, Peking University International Hospital
(P 216) LONG TERM SURVIVAL AND PROGNOSTIC FACTORS IN PATIENTS WITH PRIMARY RETROPERITONEAL LEIOMYOSARCOMA UNDERGOING SURGERIES: REAL WORLD DATA FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Xiaobing Chen
Favorite
(P 223) SURGICAL RESECTION OF RETROPERITONEAL LEIOMYOSARCOMA IN 97 CONSECUTIVE PATIENTS - EXPERIENCES FROM A CHINA RETROPERITONEAL SARCOMA REFERRAL CENTER
Xiaobing Chen
Favorite
Chepeha, Douglas

Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Douglas Chepeha
Favorite
Cherniack, Andrew

Broad Institute of MIT and Harvard
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Andrew Cherniack
Favorite
Cheung, King Kenneth

Department of Imaging and Interventional Radiology, Prince of Wales Hospital
(P 210) A LONGITUDINAL ANALYSIS OF PROGNOSTIC FACTORS IN CHINESE PATIENTS WITH RETROPERITONEAL LIPOSARCOMA
King Kenneth Cheung
Favorite
Cheung, Phyllis

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Phyllis Cheung
Favorite
Chevarie-Davis, Myriam

Hôpital Maisonneuve-Rosemont
(P 049) IMPLEMENTATION OF A ROUTINE DIAGNOSTIC NEXT GENERATION SEQUENCING PANEL OF FUSION-POSITIVE SARCOMAS: A SINGLE CENTER EXPERIENCE
Myriam Chevarie-Davis
Favorite
Chevreau, Christine

IUCT Oncopole
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Christine Chevreau
Favorite
Chianca, Vito

Clinica di Radiologia EOC IIMSI, Lugano, Switzerland
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Vito Chianca
Favorite
Chiang, Jianbang

National Cancer Centre Singapore
(P 090) TEN-YEAR INCIDENCE AND MORTALITY OF SOFT TISSUE SARCOMAS IN THE NATIONAL CANCER CENTRE SINGAPORE, FROM 2012 TO 2021
Jianbang Chiang
Favorite
Chiao, Elaine

School of Medicine, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Elaine Chiao
Favorite
Chiarappa, Frank

UC San Diego
(P 279) CEMENT AUGMENTATION WITH CEPHALLOMEDUALLARY FIXATION OF PRIMARY AND METASTATIC LESIONS OF THE PROXIMAL FEMUR.
Frank Chiarappa
Favorite
Chiarappa, Frank

University of California San Diego
(P 282) FUNGATING SOFT TISSUE SARCOMA: A COMPLEX TREATMENT DILEMMA
Frank Chiarappa
Favorite
Chibon, Frederic

8. OncoSarc, INSERM U1037, Cancer Research Center in Toulouse and Department of Pathology, Institut Claudius Régaud, IUCT-Oncopole,
(P 253) THE IMPACT OF CELL FUSION IN LEIOMYOSARCOMA ONCOGENESIS
Frederic Chibon
Favorite
Chi, Ping

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Ping Chi
Favorite
Chiusole, Benedetta

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Benedetta Chiusole
Favorite
Chi, Yueh-Yun

Children's Hospital Los Angeles
(P 037) SURVIVAL OUTCOMES AND POST-SURGICAL MORBIDITY BASED ON SURGICAL APPROACH TO PULMONARY METASTASECTOMY IN PATIENTS WITH OSTEOSARCOMA
Yueh-Yun Chi
Favorite
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Yueh-Yun Chi
Favorite
Chmielowski, Bartosz

University of California, Los Angeles
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Bartosz Chmielowski
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Bartosz Chmielowski
Favorite
(P 193) TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA
Bartosz Chmielowski
Favorite
Cho, Jae-Mun

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Jae-Mun Cho
Favorite
Chomoyan, Hripsime

Sarcoma oncology
(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Hripsime Chomoyan
Favorite
Chomoyan, Hripsime

Sarcoma Oncology Center
(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Hripsime Chomoyan
Favorite
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Hripsime Chomoyan
Favorite
Chow, Edward

Cancer Science Institute of Singapore
(P 196) THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Edward Chow
Favorite
Chow, Veronica

BC Children's Hospital, University of British Columbia
(P 033) REDUCED H3K27ME3 IMMUNOEXPRESSION IN PEDIATRIC OSTEOSARCOMA IS ASSOCIATED WITH POOR RESPONSE TO NEOADJUVENT THERAPY
Veronica Chow
Favorite
Chow, Warren

Department of Hematology/Oncology, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Warren Chow
Favorite
Choy, Edwin

Massachusetts General Hospital
(P 143) A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Edwin Choy
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Edwin Choy
Favorite
Christ, Alexander

Children's Hospital Los Angeles
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Alexander Christ
Favorite
Christensen, Anthony

St. Jude Children's Research Hospital
(P 012) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Anthony Christensen
Favorite
Christensen, James

Mirati Therapeutics
(P 193) TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA
James Christensen
Favorite
Christodoulou, Eirini

Children's Hospital Los Angeles
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Eirini Christodoulou
Favorite
Christo, Jessica

IDRx, Inc
(P 316) FIRST-IN-HUMAN PHASE 1/1B STUDY OF IDRX-42, A NOVEL ORAL TYROSINE KINASE KIT INHIBITOR, IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS
Jessica Christo
Favorite
Chua, Victoria

Sarcoma Oncology Center
(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Victoria Chua
Favorite
(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Victoria Chua
Favorite
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Victoria Chua
Favorite
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Victoria Chua
Favorite
(P 321) PHASE 1B TRIAL OF CAMSIRUBICIN, A NOVEL DOXORUBICIN ANALOG, WITH CONCOMITANT PEGFILGRASTIM FOR ADVANCED SOFT TISSUE SARCOMA TO IDENTIFY A NEW MAXIMUM TOLERATED DOSE/RECOMMENDED PHASE 2 DOSE.
Victoria Chua
Favorite
Chuba, Paul

Ascension
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Paul Chuba
Favorite
Chudasama, Priya

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Priya Chudasama
Favorite
Chugh, Rashmi

University of Michigan
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Rashmi Chugh
Favorite
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Rashmi Chugh
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Rashmi Chugh
Favorite
(P 266) EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS
Rashmi Chugh
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Rashmi Chugh
Favorite
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Rashmi Chugh
Favorite
Chung, Peter

Department of Radiation Oncology, Princess Margaret Centre, University of Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Peter Chung
Favorite
Church, Alanna

Boston Children's Hospital
(P 010) SPECTRUM OF EWING-LIKE FUSIONS AND SECONDARY GENOMIC ALTERATIONS FROM A LARGE NEXT GENERATION SEQUENCING (NGS) COMPREHENSIVE GENOMIC PROFILING (CGP) DATABASE
Alanna Church
Favorite
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Alanna Church
Favorite
(P 310) TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Alanna Church
Favorite
Cipriano, Cara

University of Pennsylvania
(P 075) EXAMINING PATIENT PERSPECTIVES ON SARCOMA SURVEILLANCE: THE SARCOMA SURVEILLANCE SURVEY
Cara Cipriano
Favorite
Clarke, Jeffrey

Duke Cancer Center
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Jeffrey Clarke
Favorite
Clerici, Elena

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Elena Clerici
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Elena Clerici
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Elena Clerici
Favorite
Coblentz, Ailish

Hospital for Sick Children and University of Toronto
(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Ailish Coblentz
Favorite
Cocchi, Claudia

Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Claudia Cocchi
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Claudia Cocchi
Favorite
Cogswell, Patricia

Cogswell Consulting, LLC
(P 194) THE EHE BIOBANK: PATIENTS POWERING RARE CANCER MODEL DEVELOPMENT & TRANSLATIONAL RESEARCH
Patricia Cogswell
Favorite
Cohen-Gogo, Sarah

Hospital for Sick Children and University of Toronto
(P 131) MUCIN 16 (CANCER ANTIGEN 125) EXPRESSION IN EPITHELIOID SARCOMA LEADS TO SINGLE-PATIENT STUDY WITH BISPECIFIC T-CELL ENGAGER UBAMATAMAB (MUCIN16-CD3): A BENCH-TO-BEDSIDE EXPERIENCE
Sarah Cohen-Gogo
Favorite
Cohen, Sean

University of Michigan Medical Center
(P 266) EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS
Sean Cohen
Favorite
Cohen, Seth

Memorial Sloan Kettering Cancer Center
(P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA
Seth Cohen
Favorite
Coker, David

The Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
David Coker
Favorite
Collaud, Stephane

Department of Thoracic Surgery, Ruhrlandklinik, University Hospital Essen, West German Cancer Center
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Stephane Collaud
Favorite
Collier, Anderson

The University of Mississippi Medical Center
(P 323) PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA.
Anderson Collier
Favorite
Collini, Paola

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Paola Collini
Favorite
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Paola Collini
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Paola Collini
Favorite
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Paola Collini
Favorite
Collins, Mike

Foghorn Therapeutics
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Mike Collins
Favorite
Collins, Natalie

Dana Farber Cancer Institute
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Natalie Collins
Favorite
Colman, Matthew

Rush University Medical Center
(P 053) PET-CT STAGING AFFECTS TIME TO TREATMENT IN SARCOMA
Matthew Colman
Favorite
(P 062) WHAT IS THE CLINICAL IMPACT OF STAGING AND SURVEILLANCE PET-CT SCAN FINDINGS IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA?
Matthew Colman
Favorite
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Matthew Colman
Favorite
(P 086) RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Matthew Colman
Favorite
(P 094) TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS IS UNCOMMON AFTER INTRALESIONAL CURETTAGE IN GIANT CELL TUMOR OF BONE
Matthew Colman
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Matthew Colman
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Matthew Colman
Favorite
(P 273) 3D-PRINTED PATIENT-SPECIFIC CUTTING GUIDES VERSUS FREEHAND RESECTION FOR INTERNAL HEMIPELVECTOMY: CLINICAL AND ONCOLOGIC OUTCOMES
Matthew Colman
Favorite
(P 277) BEARING SELECTION IN PROXIMAL FEMORAL REPLACEMENT: A COMPARISON OF CLINICAL OUTCOMES
Matthew Colman
Favorite
(P 283) HIP ARTHROPLASTY OUTCOMES IN METASTATIC BONE DISEASE
Matthew Colman
Favorite
(P 287) INTERNAL HEMIPELVECTOMY: A SINGLE INSTITUTION'S LEARNING CURVE AND LONGITUDINAL EXPERIENCE
Matthew Colman
Favorite
(P 295) PERIACETABULAR INTERNAL HEMIPELVECTOMY WITH AND WITHOUT SACRAL RESECTION: AN INSTITUTIONAL EXPERIENCE AND SYSTEMATIC REVIEW
Matthew Colman
Favorite
(P 300) RECONSTRUCTION FOLLOWING SACROILIAC TUMOR RESECTION: A SYSTEMATIC REVIEW
Matthew Colman
Favorite
Colombo, Chiara

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Chiara Colombo
Favorite
Colombo, Piergiuseppe

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy. Department of Pathology, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Piergiuseppe Colombo
Favorite
Colombo, Piergiuseppe

Pathology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Piergiuseppe Colombo
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Piergiuseppe Colombo
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Piergiuseppe Colombo
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Piergiuseppe Colombo
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Piergiuseppe Colombo
Favorite
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Piergiuseppe Colombo
Favorite
Comandone, Alessandro

Oncology Department, ASL Città di Torino
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Alessandro Comandone
Favorite
Comandone, Alessandro

Humanitas Gradenigo Hospital, Turin, Italy
(P 162) PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Alessandro Comandone
Favorite
Comeau, Hannah

Dana-Farber Cancer Insitute
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Hannah Comeau
Favorite
Conley, Anthony

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Anthony Conley
Favorite
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Anthony Conley
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Anthony Conley
Favorite
Connolly, Elizabeth

Chris O'Brien Lifehouse
(P 149) CHARACTERISTICS OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS REFERRED TO A DEDICATED EARLY PHASE CLINICAL TRIAL CLINIC
Elizabeth Connolly
Favorite
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Elizabeth Connolly
Favorite
Constans, Jean-Marc

CHU AMIENS
(P 080) INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Jean-Marc Constans
Favorite
Cooney, Tabitha

Dana-Farber Cancer Institute
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Tabitha Cooney
Favorite
Corbitt, Devin

Humanitas University
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Devin Corbitt
Favorite
Cordero, Camille

Institut Curie
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Camille Cordero
Favorite
Cordle, Andrew

University of Pittsburgh Medical Center
(P 087) RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Andrew Cordle
Favorite
Corn, Sarah

McGill University
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Sarah Corn
Favorite
Corradini, Nadège

IHOPe
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Nadège Corradini
Favorite
(P 270) ORAL VINORELBINE ACTIVITY FOR PROGRESSIVE DESMOID FIBROMATOSIS TUMOURS IN YOUNG PATIENTS
Nadège Corradini
Favorite
Corson, Bailey

Naval Medical Center San Diego
(P 282) FUNGATING SOFT TISSUE SARCOMA: A COMPLEX TREATMENT DILEMMA
Bailey Corson
Favorite
Cosci, Ilaria

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Ilaria Cosci
Favorite
Costa, Philippos

University of Miami/Sylvester Comprehensive Cancer Center
(P 07) HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Philippos Costa
Favorite
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Philippos Costa
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Philippos Costa
Favorite
Costa, Philippos

Yale University
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Philippos Costa
Favorite
Cote, Gregory

Massachusetts General Hospital
(P 143) A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Gregory Cote
Favorite
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Gregory Cote
Favorite
Couch, Cory

Mayo Clinic
(P 302) SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Cory Couch
Favorite
Coward*, Victoria

Lunenfeld-Tanenbaum Research Institute
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Victoria Coward*
Favorite
(P 233) DETERMINING THE CONTRIBUTIONS OF PD-L1 AND STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT
Victoria Coward*
Favorite
Cowie, Fiona

Beatson West of Scotland Cancer Centre
(P 073) EVALUATING DISTRESS AND THE PATIENT EXPERIENCE OF SARCOMA PATIENTS IN THE WEST OF SCOTLAND
Fiona Cowie
Favorite
Coy, Kathy

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Kathy Coy
Favorite
Crago, William

Inhibrx, Inc
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
William Crago
Favorite
Crane, Jacquelyn

Stanford University
(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Jacquelyn Crane
Favorite
Cranmer, Lee

Fred Hutchinson – University of Washington Cancer Consortium
(P 063) A RETROSPECTIVE COHORT ANALYSIS EVALUATING THE NATURAL HISTORY AND CHARACTERISTICS OF ANGIOSARCOMAS OF THE BREAST
Lee Cranmer
Favorite
(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Lee Cranmer
Favorite
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Lee Cranmer
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Lee Cranmer
Favorite
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Lee Cranmer
Favorite
Crawford, Brooke

University of Miami
(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Brooke Crawford
Favorite
Cribbs, Adam

University of Oxford
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Adam Cribbs
Favorite
Crimella, Jessica

Moffitt Cancer Center
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Jessica Crimella
Favorite
Cripe, Timothy

Division of Hematology and Oncology, Nationwide Children’s Hospital, Department of Pediatrics, The Ohio State University Wexner College of Medicine
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Timothy Cripe
Favorite
Crippa, Noemi

University of Milan
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Noemi Crippa
Favorite
Crockett, David

Nebraska Cancer Specialists
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
David Crockett
Favorite
Crompton, Joseph

UCLA Health
(P 173) DYSREGULATION OF MITOCHONDRIAL DYNAMICS IN WELL-DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA PROVIDES A UNIQUE SUSCEPTABILITY TO NOVEL THERAPY
Joseph Crompton
Favorite
Cross, William

University college London, Cancer Institute
(P 011) TACKLE A RARE SARCOMA THROUGH A COLLABORATIVE APPROACH
William Cross
Favorite
Crow, Jesse

Nationwide Children's Hospital
(P 229) CHARACTERIZING THE MICROSATELLITE-BINDING FUNCTION OF EWS-FLI AND ETV6 IN EWING SARCOMA
Jesse Crow
Favorite
Cruz Casadevall, Jordi

ICO
(P 113) PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
Jordi Cruz Casadevall
Favorite
Cruz, Josefina

HU Canarias
(P 113) PROGNOSTIC AND/OR PREDICTIVE VALUE OF EXON 11 MUTATIONS IN TUMOR RESPONSE TO IMATINIB IN METASTATIC GASTROINTESTINAL STROMAL TUMOR :RETROSPECTIVE ANALYSIS OF A MULTICENTRIC NATIONAL REGISTRY
Josefina Cruz
Favorite
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Josefina Cruz
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Josefina Cruz
Favorite
Culbertson, Timothy

McGovern Medical School
(P 248) RESULTS OF A NEOADJUVANT REGIMEN USING A FIXED DOSE OF ADRIAMYCIN AS AN ELECTRON AFFINIC AGENT WITH 27GY FOLLOWED BY WIDE LOCAL RESECTION OF SOFT TISSUE SARCOMAS
Timothy Culbertson
Favorite
Currier, Mark

Center for Childhood Cancer, Nationwide Children’s Hospital
(P 140) TRABECTEDIN ENHANCES ONCOLYTIC HERPES SIMPLEX VIROIMMUNOTHERAPY BY REDUCING BARRIERS TO VIRUS SPREAD AND IMMUNE EFFECTOR FUNCTION IN PRECLINICAL BONE SARCOMA MODELS
Mark Currier
Favorite
Cury, Fabio

McGill University Health Centre
(P 092) THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Fabio Cury
Favorite
Cyprova, Sona

Charles University, Motol Children´s Hospital
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Sona Cyprova
Favorite
Czarnecka, Anna

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Anna Czarnecka
Favorite